Literature DB >> 7247783

Plasmapheresis in refractory generalized myasthenia gravis.

P Kornfeld, E P Ambinder, T Mittag, A N Bender, A E Papatestas, J Goldberg, G Genkins.   

Abstract

A group of 16 patients with severe generalized myasthenia gravis (MG) (five with thymoma) that was resistant to anticholinesterases, thymectomy, and corticosteroids were treated by plasmapheresis. Twelve patients showed an excellent clinical response. Plasmapheresis is an effective treatment modality for many patients with severe generalized MG resistant to other forms of therapy. Unfortunately, the beneficial results are only transient and periodic plasmapheresis treatments are necessary.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7247783     DOI: 10.1001/archneur.1981.00510080040003

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

Review 1.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

2.  [Correlation of acetylcholine receptor antibodies and clinical severity of myasthenia gravis in combined immunosuppressive therapy].

Authors:  F Schumm; A Fateh-Moghadam; J Dichgans
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

Review 3.  Immunopathology of acetylcholine receptors in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  Intravenous immunoglobulin for myasthenia gravis.

Authors:  Philippe Gajdos; Sylvie Chevret; Klaus V Toyka
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

5.  A short plasma exchange protocol is effective in severe myasthenia gravis.

Authors:  C Antozzi; M Gemma; B Regi; E Berta; P Confalonieri; D Peluchetti; R Mantegazza; F Baggi; M Marconi; F Fiacchino
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

6.  Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis.

Authors:  Jeffrey T Guptill; Vern C Juel; Janice M Massey; Amanda C Anderson; Manisha Chopra; John S Yi; Ehsanollah Esfandiari; Tim Buchanan; Bryan Smith; Paul Atherfold; Emma Jones; James F Howard
Journal:  Autoimmunity       Date:  2016-08-11       Impact factor: 2.815

7.  Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravis: a randomised trial.

Authors:  Isha Trikha; Sumit Singh; Vinay Goyal; Garima Shukla; Rama Bhasin; Madhuri Behari
Journal:  J Neurol       Date:  2007-08-11       Impact factor: 4.849

8.  Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy.

Authors:  Kentaro Deguchi; Kosuke Matsuzono; Yumiko Nakano; Syoichiro Kono; Kota Sato; Shoko Deguchi; Katsuyuki Tanabe; Nozomi Hishikawa; Yasuyuki Ota; Toru Yamashita; Kiyoe Ohta; Masakatsu Motomura; Koji Abe
Journal:  Intern Med       Date:  2018-01-11       Impact factor: 1.271

Review 9.  Plasma exchange for myasthenia gravis.

Authors:  P Gajdos; S Chevret; K Toyka
Journal:  Cochrane Database Syst Rev       Date:  2002
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.